Suppliers and packagers for mestinon

mestinon

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch	MESTINON	pyridostigmine bromide	SYRUP;ORAL	015193	NDA	Bausch Health US, LLC	0187-3012-20	473 mL in 1 BOTTLE (0187-3012-20)	1965-01-25
Bausch	MESTINON	pyridostigmine bromide	SYRUP;ORAL	015193	NDA AUTHORIZED GENERIC	Oceanside Pharmaceuticals	68682-307-05	473 mL in 1 BOTTLE (68682-307-05)	2019-07-01
Bausch	MESTINON	pyridostigmine bromide	TABLET, EXTENDED RELEASE;ORAL	011665	NDA	Bausch Health US, LLC	0187-3013-30	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-3013-30)	1959-01-12

MESTINON (Pyridostigmine Bromide) Supply Chain Analysis

Last updated: February 19, 2026

This report identifies key suppliers of pyridostigmine bromide, the active pharmaceutical ingredient (API) in MESTINON, and analyzes their production capabilities, regulatory standing, and historical supply performance. The analysis focuses on the critical role these suppliers play in ensuring the consistent availability of this essential medication for patients with myasthenia gravis and other neuromuscular disorders.

What is MESTINON and its Market Significance?

Mestinon is a brand name for pyridostigmine bromide, a reversible cholinesterase inhibitor. It works by increasing the level of acetylcholine, a neurotransmitter, at neuromuscular junctions, thereby improving muscle strength in patients with myasthenia gravis. It is also used to counteract the effects of certain muscle relaxants post-surgery and in managing congenital myasthenic syndromes. The global market for Mestinon is stable, driven by a consistent patient population requiring long-term treatment. The primary challenge for the supply chain is ensuring uninterrupted availability due to the critical nature of the drug for its patient demographic.

Who are the Primary Suppliers of Pyridostigmine Bromide API?

The supply chain for pyridostigmine bromide API is characterized by a limited number of manufacturers possessing the necessary expertise and regulatory approvals. These suppliers are crucial for maintaining the global availability of Mestinon.

• Hospira, Inc. (a Pfizer company): Historically a significant producer and supplier of pyridostigmine bromide for both its own finished drug products and potentially for other pharmaceutical companies. Pfizer acquired Hospira in 2015, consolidating its position in the injectable and sterile drug manufacturing space.
• Daiichi Sankyo Company, Limited: A Japanese pharmaceutical company that has been involved in the production and supply of pyridostigmine bromide.
• Mallinckrodt plc: While Mallinckrodt has faced challenges, it has been a historical supplier of various APIs, and its involvement in pyridostigmine bromide production requires verification of current operational status and regulatory compliance.
• Patheon (a Thermo Fisher Scientific brand): As a contract development and manufacturing organization (CDMO), Patheon may produce pyridostigmine bromide for pharmaceutical clients, depending on specific contracts and its API manufacturing capabilities at particular sites.

The precise list of current, active API manufacturers can fluctuate due to market dynamics, regulatory changes, and business decisions. Pharmaceutical companies often maintain relationships with multiple qualified suppliers to mitigate risk.

What are the Regulatory Requirements for Pyridostigmine Bromide API Manufacturing?

The manufacturing of Active Pharmaceutical Ingredients (APIs) for human use is strictly regulated by health authorities worldwide to ensure product quality, safety, and efficacy. For pyridostigmine bromide, key regulatory considerations include:

• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to current GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes stringent controls over raw materials, manufacturing processes, quality control testing, documentation, and facility maintenance.
  • FDA: U.S. Code of Federal Regulations, Title 21, Part 210 and 211.
  • EMA: EudraLex Volume 4.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the chemistry, manufacturing, and controls of the API. Pharmaceutical companies that use the API in their finished drug products can reference these DMFs in their marketing authorization applications.
  • Type II DMF (FDA): Contains information on drug substance, manufacturing process, and controls.
• Site Inspections and Audits: Manufacturing sites are subject to regular inspections by regulatory authorities. Pharmaceutical companies also conduct their own audits of API suppliers to ensure compliance and quality standards.
• Impurity Profiling and Control: Manufacturers must identify, quantify, and control all impurities in the API, including residual solvents, related substances, and potential genotoxic impurities, according to International Council for Harmonisation (ICH) guidelines.
  • ICH Q3A (R2): Impurities in New Drug Substances.
  • ICH Q3C (R6): Impurities: Guideline for Residual Solvents.
• Stability Testing: APIs must undergo stability testing to determine their shelf life and appropriate storage conditions.
  • ICH Q1A (R2): Stability Testing of New Drug Substances and Products.
• Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of the supply chain from API manufacturer to finished product.

Manufacturers operating in multiple jurisdictions must comply with the GMP and regulatory requirements of each region where their product will be marketed.

What is the Historical Production Capacity and Performance of Key Suppliers?

Assessing historical production capacity and performance for specific APIs like pyridostigmine bromide can be challenging due to proprietary business information. However, general trends and past performance can be inferred from market availability and regulatory actions.

• Hospira/Pfizer: As a major player in sterile injectables and historically a significant supplier of pyridostigmine bromide, Hospira/Pfizer has demonstrated substantial production capacity. Its integrated manufacturing capabilities suggest a robust supply chain, though any disruptions would have a considerable impact due to its market share. Regulatory filings and inspection histories with the FDA are publicly accessible and provide insights into compliance.
• Daiichi Sankyo: While Daiichi Sankyo is a global pharmaceutical company, its specific API manufacturing capacity for pyridostigmine bromide and its historical performance as a standalone API supplier are less transparently documented in public domain compared to larger API-focused manufacturers or CDMOs.
• Mallinckrodt: Mallinckrodt has a history of API manufacturing, but recent financial restructuring and regulatory scrutiny on certain product lines warrant careful due diligence regarding its current capacity and reliability for pyridostigmine bromide. Past production levels would need to be correlated with periods of market availability and any reported shortages.
• Patheon/Thermo Fisher Scientific: As a CDMO, Patheon's capacity for pyridostigmine bromide is dictated by client demand and their facility's specific equipment and expertise. Their performance is tied to their contractual obligations and track record in meeting client specifications and timelines. Their network of facilities offers flexibility but also requires specific site-level assessment.

Evidence of Supply Chain Fragility:

Historically, the pharmaceutical supply chain for various essential medicines, including those for rare diseases or with limited manufacturers, has shown vulnerabilities. This has been evidenced by:

• Drug Shortages: The FDA's Drug Shortages list periodically includes products or their active ingredients, indicating production issues, quality problems, or demand spikes that outstrip supply. While specific pyridostigmine bromide API shortages are not always explicitly detailed, disruptions in API supply can lead to finished product shortages.
• Regulatory Actions: Warning letters or import alerts issued by regulatory agencies to API manufacturers can immediately halt production or shipments, causing significant supply chain disruptions. A review of FDA enforcement actions for the identified suppliers would provide further insight.

Companies relying on these suppliers must engage in robust risk management, including dual sourcing strategies where feasible, regular supplier audits, and close monitoring of regulatory landscapes.

What are the Current Market Dynamics and Future Outlook for Pyridostigmine Bromide API Supply?

The market for pyridostigmine bromide API is driven by established demand from the approved indications. The outlook is generally stable but influenced by several factors:

• Patient Population Stability: Myasthenia gravis and related conditions are chronic, requiring long-term treatment. This provides a consistent, predictable demand for pyridostigmine bromide.
• Limited New Entrants: The complex regulatory pathway and specialized manufacturing requirements for APIs can deter new manufacturers from entering the market for established drugs like pyridostigmine bromide.
• Focus on Supply Chain Resilience: Following global events that have highlighted supply chain vulnerabilities, pharmaceutical companies are increasingly prioritizing supply chain resilience. This includes:
  • Diversification of Suppliers: Actively seeking and qualifying secondary or tertiary suppliers for critical APIs.
  • Geographic Diversification: Reducing reliance on single manufacturing sites or regions.
  • Inventory Management: Adjusting inventory levels to buffer against potential disruptions.
• Generic Competition: While Mestinon is a branded product, the availability of generic versions of pyridostigmine bromide can influence API demand dynamics. Multiple finished product manufacturers may rely on the same pool of API suppliers.
• Technological Advancements in Manufacturing: While the core synthesis of pyridostigmine bromide is established, improvements in process efficiency, impurity control, and sustainability in API manufacturing could emerge from existing or new suppliers.
• Regulatory Scrutiny: Ongoing and increasing regulatory oversight globally means that API manufacturers must maintain impeccable quality and compliance records. Any lapse can lead to significant supply disruptions. For example, changes in impurity limits or new analytical method requirements could necessitate process revalidation.

The future supply of pyridostigmine bromide API is therefore likely to remain in the hands of a relatively small number of established, compliant manufacturers. Strategic partnerships and rigorous supplier qualification will be paramount for finished product manufacturers to ensure uninterrupted patient access.

What are the Risks and Mitigation Strategies for Pyridostigmine Bromide API Sourcing?

Sourcing pyridostigmine bromide API presents several risks that necessitate strategic mitigation.

Supply Risks

• Single Source Dependence: Reliance on a single API manufacturer creates significant vulnerability. If this supplier experiences production issues, regulatory actions, or business insolvency, supply can be severely impacted.
• Quality Control Failures: Batch failures due to deviations from GMP or unexpected impurity profiles can lead to delays, product recalls, and shortages.
• Regulatory Non-Compliance: A manufacturer receiving warning letters, import alerts, or facing other enforcement actions from health authorities can cease production or shipping of their API.
• Geopolitical Instability: Suppliers located in regions prone to political unrest, trade disputes, or natural disasters face inherent risks that can disrupt manufacturing and logistics.
• Capacity Constraints: Unexpected surges in demand, or underinvestment in production capacity by existing suppliers, can lead to an inability to meet market needs.
• Raw Material Scarcity: Disruptions in the supply of key starting materials or intermediates for pyridostigmine bromide synthesis can halt API production.

Mitigation Strategies

• Dual or Multi-Sourcing: Qualify and maintain relationships with at least two distinct API suppliers, preferably in different geographic locations. This requires significant investment in supplier audits, quality agreements, and potentially dual inventory.
• Robust Supplier Qualification and Auditing Program: Implement a comprehensive program that goes beyond basic regulatory compliance. This includes assessing financial stability, business continuity plans, risk management frameworks, and historical performance. Regular, unannounced audits are crucial.
• Strong Quality Agreements: Establish detailed quality agreements with API suppliers that clearly define responsibilities, specifications, change control procedures, and communication protocols for deviations and investigations.
• Proactive Regulatory Monitoring: Continuously monitor regulatory updates, enforcement actions, and inspection outcomes related to all qualified API suppliers.
• Supply Chain Mapping: Understand the upstream supply chain for critical raw materials used by API manufacturers to identify potential single points of failure further down the chain.
• Contingency Planning and Inventory Buffers: Develop contingency plans for supply disruptions. Maintain appropriate inventory levels of API and finished product to buffer against short-term supply interruptions, balancing inventory holding costs with risk.
• Strategic Partnerships and Long-Term Contracts: Negotiate long-term supply agreements that provide price stability, guaranteed supply volumes, and clear escalation clauses.
• Investigate Alternative Synthetic Routes or Technologies: While challenging for established APIs, explore possibilities for alternative manufacturing processes that might be less reliant on specific raw materials or less susceptible to certain production bottlenecks.

Effective risk mitigation requires a proactive, data-driven approach that involves close collaboration between procurement, quality assurance, regulatory affairs, and manufacturing departments within a pharmaceutical company.

Key Takeaways

• The supply of pyridostigmine bromide API is concentrated among a limited number of manufacturers with specialized expertise and stringent regulatory compliance.
• Key suppliers historically and potentially currently include entities such as Hospira (Pfizer), Daiichi Sankyo, and potentially contract manufacturers like Patheon.
• Adherence to current Good Manufacturing Practices (cGMP) and comprehensive Drug Master Files (DMFs) are non-negotiable regulatory requirements for API production.
• Historical supply performance is inferred from market availability and regulatory actions; past disruptions have underscored the fragility of specialized API supply chains.
• The future outlook for pyridostigmine bromide API supply is stable, driven by consistent patient demand, but increasingly emphasizes supply chain resilience through diversification and proactive risk management.
• Primary supply risks include single-source dependence, quality failures, and regulatory non-compliance, which necessitate mitigation strategies such as dual-sourcing, robust auditing, and strong quality agreements.

Frequently Asked Questions

1. Are there any new manufacturers expected to enter the pyridostigmine bromide API market? The entry of new API manufacturers for established drugs like pyridostigmine bromide is uncommon due to significant regulatory hurdles, specialized manufacturing knowledge, and established relationships between existing suppliers and finished product manufacturers.

2. What is the typical lead time for ordering pyridostigmine bromide API from a qualified supplier? Lead times can vary significantly but typically range from 3 to 9 months. This includes manufacturing time, quality control testing, and shipment, and can be longer for custom orders or if the supplier has a heavily backlogged production schedule.

3. How does the FDA's inspection schedule impact API suppliers? The FDA conducts periodic inspections to ensure GMP compliance. A supplier's successful inspection history is critical for their continued ability to supply APIs to the U.S. market. An unsuccessful inspection or a warning letter can immediately halt shipments, creating significant supply chain disruption.

4. What are the major quality control parameters tested for pyridostigmine bromide API? Key quality control parameters include assay (potency), identification, purity (related substances, residual solvents, heavy metals), moisture content, and physical characteristics (e.g., particle size distribution, if relevant for formulation).

5. How do pharmaceutical companies typically ensure a consistent supply of Mestinon finished product? Companies ensure consistent supply by qualifying multiple API suppliers, establishing strong long-term contracts with preferred suppliers, maintaining adequate safety stock of both API and finished product, and actively monitoring the regulatory and operational status of their entire supply chain.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-regulation/current-good-manufacturing-practice-cgmp-regulations [2] European Medicines Agency. (n.d.). EudraLex Volume 4 - Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/pharmaceuticals/guidance-regulation/eudralex/eudralex-volume-4 [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/products/guidelines [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process/drug-master-files-dmfs [5] Pfizer Inc. (2024). Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Retrieved from https://www.pfizer.com/investors/sec-filings (Note: Actual link may vary annually and should be checked on the investor relations site). [6] Daiichi Sankyo Company, Limited. (2023). Integrated Report 2023. Retrieved from https://www.daiichisankyo.com/ir/library/report/index.html (Note: Specific report names and links can change). [7] Thermo Fisher Scientific Inc. (2023). Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Retrieved from https://ir.thermofisher.com/sec-filings (Note: Actual link may vary annually and should be checked on the investor relations site).